This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Emerging Interleukin-5 (IL-5) Antagonists Based Therapies for Eosinophilic Asthma

Emerging Interleukin-5 (IL-5) Antagonists Based Therapies for Eosinophilic Asthma

Format

Webcast

Time to Complete

1 hour

Released

October 31, 2016

Expires

October 31, 2017
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider



Jointly provided by A. Webb Roberts Center for CME of Baylor Scott & White Health and MedNet

Commercial Supporter

Supported by GlaxoSmithKline, LLC

Program Description

This webcast is intended to improve care of patients with eosinophilic asthma by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

Intended Audience

This webcast is designed to meet the educational needs of asthma specialists, pulmonologists, immunologists, primary care physicians, nurse practitioners, physician assistants as well as other health care professionals involved in the care of patients with eosinophilic asthma.

Educational Objectives

As a result of participating in the activity, learners should be better able to:

  • Assess eosinophils as phenotypic biomarker and its relation to exacerbations, decline in lung function, and asthma control
  • Apply emerging interleukin-5 (IL-5) antagonists based therapies in patients with eosinophilic asthma

Conflict Of Interest Disclosure Policy

It is the policy of the A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health, Dallas to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.

Every person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose.

Faculty

Mario Castro, MD
Alan A. and Edith L. Wolff Professor of Pulmonary and Critical Care Medicine
Professor of Medicine
Pediatrics, and Radiology
Washington University School of Medicine
St. Louis, MO

Dr. Castro discloses the following:
Principal Investigator (University Grant Funding): AsthmaNet, American Lung Association, Severe Asthma Research Program;
Principal Investigator (Pharmaceutical Grant Funding): Amgen, Boehringer Ingelheim, Genentech, Gilead, GSK, Invion, Johnson&Johnson, Medimmune/AstraZeneca, Novartis, Pfizer, Sanofi Aventis, Teva, Vectura
Consultant: AstraZeneca, Boston Scientific, Holaira, NeoStem, Neutronic, Novartis, Roche, Sanofi Aventis, Teva, Therabron
Speaker: Boehringer Ingelheim, Boston Scientific, Genentech, Teva
Royalties: Elsevier
Stock Options: Sparo Inc.

Leonard B. Bacharier, MD
Donald B. Strominger Professor of Pediatrics
Washington University School of Medicine
St. Louis, MO

Dr. Bacharier discloses the following:
Consultant: Teva, DBV Technologies. Genentech, Novartis, Boehringer-Ingelheim, Meda, Vectura
Speaker’s Bureau: Teva, Boehringer-Ingelheim; JACI Associate Editor: Elsevier/AAAAI; Director: ABAI

Planners' and Managers' Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

Mario Castro, MD, discloses the following:
Principal Investigator (University Grant Funding): AsthmaNet, American Lung Association, Severe Asthma Research Program;
Principal Investigator (Pharmaceutical Grant Funding): Amgen, Boehringer Ingelheim, Genentech, Gilead, GSK, Invion, Johnson&Johnson, Medimmune/AstraZeneca, Novartis, Pfizer, Sanofi Aventis, Teva, Vectura
Consultant: AstraZeneca, Boston Scientific, Holaira, NeoStem, Neutronic, Novartis, Roche, Sanofi Aventis, Teva, Therabron; Speaker: Boehringer Ingelheim, Boston Scientific, Genentech, Teva
Royalties: Elsevier
Stock Options: Sparo Inc.

Kamatham A. Naidu, PhD (CancerNet), has no relevant financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of A. Webb Roberts Center for CME of Baylor Scott & White Health and MedNet. The A. Webb Roberts Center for CME of Baylor Scott & White Health is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

It is the policy of the A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health, Dallas to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.

Disclaimer

The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

NON-ENDORSEMENT OF PRODUCTS
The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health, Dallas do not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.

Instructions

There are no fees for participating in or receiving credit for this webcast. During the period October 31, 2016 through October 31, 2017, participants must read all of the material and study the educational webcast.

This webcast includes text, graphics, and may include multimedia features.

To obtain credit, a score of 80% or above on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact the CME Provider at 214-820-2317.

If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

A. Webb Roberts Center for CME of Baylor Scott & White Health observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support.

myCME privacy policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue